Sinovac Biotech SVA
NASDAQ SVA
$6.47 +0.00 (+0.00%)
At close: Oct 28, 2026 · 4:00 PM EDT

Sinovac Biotech (SVA) Convertible Debt (2020)

Updated

Sinovac Biotech's Convertible Debt was $14.69 million in Q3 2020, up 0.2% from the prior quarter.

Analysis

Sinovac Biotech (SVA) Convertible Debt (2020) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Sinovac Biotech 464.94 Mn -24.98 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 14.69 Mn
Jun 30, 2020 14.66 Mn
API Access

Sinovac Biotech Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=SVA&period=max&api_key=YOUR_API_KEY